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Serum lipids act as inverse acute phase reactants
and are falsely low in patients with critical
limb ischemia
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Background: Lipid levels generally fall after an acute myocardial infarction. This study was conducted to see what trends
lipid levels had in patients who underwent operation for critical limb ischemia.
Methods: The study was prospective and included 30 patients who underwent operation for critical limb ischemia. Serum
lipid profiles and C-reactive protein were analyzed before surgery and 3 months after peripheral bypass surgery. In
addition, comparison of lipid levels after surgery was made with 287 healthy and 283 ischemic heart disease controls from
The Copenhagen City Heart Study.
Results: Total, low density lipoprotein, and high density lipoprotein cholesterol levels were found to be significantly lower
before surgery than 3 months after surgery (P < .001). In contrast, C-reactive protein was higher before surgery and
decreased after 3 months (P < .0001). An inverse linear correlation was found between total cholesterol/low density
lipoprotein cholesterol and C-reactive protein (P < .001 and P < .04, respectively). Comparison with controls showed
that cholesterol levels 3 months after surgery were significantly lower (P < .009).
Conclusion: Serum cholesterol levels are not reliable in the preoperative period and should therefore be measured at least
3 months after surgery when they seem to approach a more representative level. (J Vasc Surg 2002;36:1005-10.)
It is now well established that hyperlipidemia is a mod-
ifiable risk factor for atherosclerosis, conferring significant
reductions in both cardiac morbidity and mortality rates.1-5
In patients who undergo peripheral arterial revasculariza-
tion, the presence of coronary artery disease has been
identified in up to 90% after angiography.6 The mortality
rate in this group is about 10% to 20% per annum.7,8
Therefore, active treatment of hypercholesterolemia could
prove to be highly beneficial in this patient group, with
regards to reducing cardiac morbidity and mortality rates,8
even though the recent Heart Protection Study apparently
showed a significant effect.9
Although evidence exists that every patient with mani-
festations of atherosclerotic disease would probably stand
to benefit from treatment with antihyperlipidemics, current
guidelines still dictate treatment protocols for most physi-
cians. Therefore, instituting appropriate antihyperlipidemic
treatment is entirely reliant on a dependable measurement
of serum lipids.10,11 Several studies have reported that
serum lipids drawn on admission for an acute myocardial
infarction are not representative of baseline values.12-19
Whether this is also true in patients with severe peripheral
arterial disease is, however, unknown. Consequently, treat-
ment may be delayed or never instituted. Because of the
benefits of medicinal lowering of serum lipids, current
treatment guidelines advocate an aggressive approach.10,11
With this in mind, this study was initiated to: 1, deter-
mine the natural course of lipid levels in patients with
critical limb ischemia, measured before surgery and 3
months after bypass surgery; and 2, to investigate whether
lipids and C-reactive protein were interrelated. To set the
blood values for our cases in perspective, two case-control
studies were performed comparing cases with controls free
of cardiac disease and controls with ischemic heart disease
(IHD).
MATERIALS AND METHODS
Patients. This study included 30 consecutive patients
with peripheral critical ischemia admitted to the Depart-
ment of Vascular Surgery at Gentofte University Hospital
for bypass surgery. Critical ischemia was defined according
to the Second European Consensus document. No patient
was currently or had previously been taking antihyperlipi-
demics, nor had any patient previously been treated with
diet for hyperlipidemia. Serum lipids were drawn before
surgery. To monitor nutritional status, albumin was also
measured. Reassessment was performed 3 months after
surgery in the outpatient clinic. All but one bypass graft
were patent at 3 months postoperative control evaluated
with ultrasound duplex scanning.
Controls. The 30 patients included in this study were
matched for gender and age to participants in the Copen-
hagen City Heart Study, a population study with 10,049
participants. Participants in the Copenhagen City Heart
Study were randomly selected from the city of Copenha-
gen, with the goal of obtaining a representative sample of
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the general adult Danish population. The study design can
be seen in Fig 1. As illustrated, cases were compared with
participants of The Copenhagen City Heart Study who
remained free of cardiac disease (healthy) and those who
had had IHD develop (verified until 1997 with review of all
hospital admissions and diagnoses entered into the Danish
National Hospital Discharge Register, all deaths entered in
the Danish National Register of Cause of Death, and
medical records from hospitals and general practitioners).
We attempted to match a maximum of 10 healthy and IHD
controls from The Copenhagen City Heart Study to each of
the 30 patients who underwent operation for lower limb
ischemia, but in some cases, fewer controls were found. The
number of controls, however, was never less than 6 for each
case, which resulted in a total of 287 healthy and 283 IHD
control subjects.
Biochemical analysis. All preoperative and postoper-
ative blood samples were determined from a venous punc-
ture and analyzed by Gentofte Hospital laboratory staff.
C-reactive protein was analyzed with the particle enhanced
immunoturbidimetric method. Cholesterol (total, low
density lipoprotein [LDL], and high density lipoprotein
[HDL]), triglycerides, and albumin were analyzed with the
enzymatic colorimetric method. Precision of laboratory
cholesterol levels were assessed with two or three control
seras. Coefficient of variation for total cholesterol was 1.4%
and for LDL and HDL cholesterol was 3.0% and 2.7%,
respectively. For triglycerides, the coefficient was 3.1%; for
albumin, the coefficient was 3.2%; and for C-reactive pro-
tein, it was 3.4%. Furthermore, the laboratory was sub-
jected to routine external quality control. In the Copenha-
gen City Heart Study, cholesterol (total, LDL, HDL) was
also analyzed with the enzymatic colorimetric method.
Coefficient of variation for total cholesterol was 2.1% and
for LDL and HDL cholesterol was 1.9%.
Statistics. All statistical analyses were carried out on
SPSS 10.0 (SPSS Inc, Chicago, Ill). Wilcoxon signed rank
test and Mann-Whitney U tests were used to assess statis-
tical significance. The R2 values quoted on the scatter plots
were based on Pearson correlations. P values of less than .05
were considered to indicate statistical significance.
RESULTS
Participant clinical characteristics are noted in Table I.
The median age of the 30 patients (15 male, 15 female) was
71 years (range, 42 to 89 years).
After surgery, three patients had persistent intermittent
claudication, one had critical ischemic pain from graft
occlusion, and five had nonhealed ischemic ulcers; how-
ever, most patients had improved perfusion of the recon-
structed lower limb, as evidenced by an increase in ankle/
brachial index from 0.39 to 0.81 (Table II). In Table II and
Figs 2, 3, and 4, the changes in laboratory blood values
before and after surgery are shown. A highly significant
elevation of the lipid profile up to 33% and a decrease in
C-reactive protein of 81% were observed. Cholesterol levels
for patients with critical limb ischemia 3 months after
surgery were significantly lower for both total and LDL
cholesterol compared with healthy controls and IHD con-
trol subjects. HDL cholesterol was significantly higher in
patients 3 months after surgery compared with IHD con-
trol subjects (Table III).
The differences seen in total cholesterol and LDL
cholesterol values were recognized as having an inverse
linear correlation to C-reactive protein (P values  .001
and  .04, respectively). The correlation between
Fig 1. Study design.
Table I. Clinical characteristics of study participants
Patient
(n  30)
Copenhagen City Heart Study
Healthy
controls
(n  287)
IHD
controls
(n  283)
Smoking
Current 64% 21% 25%
Former 23% 41% 30%
Never 13% 38% 45%
Hypertension 50% 58% 41%
Diabetes mellitus 26% 6% 33%
Cerebrovascular disease 20% 8% –
IHD 17% 0 100%
Preoperative
electrocardiogram
Ischemia 20% – –
Myocardial Infarction 27% – –
Atrial fibrillation 20% – –
Normal 33% – –
Operative indication
Rest pain 37% – –
Ischemic ulcer 37% – –
Gangrene 26% – –
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change in total cholesterol and C-reactive protein
yielded an r 2 value of 0.40, indicating that 40% of the
variability of the data could be explained by the associa-
tion between these two variables. Likewise, 18% of vari-
ation of the change in C-reactive protein may be ex-
plained by LDL cholesterol (Figs 5 and 6). No significant
correlation was noted between C-reactive protein and
HDL cholesterol nor between C-reactive protein and
triglycerides (data not shown).
Although 63% of the patients had ischemic ulcer or
gangrene, no difference in C-reactive protein level was
noted when compared with those with rest pain. Nor was
the inverse relationship with lipids particularly notable
among patients with ulcer/gangrene compared with those
with rest pain.
DISCUSSION
In this study, we have shown that cholesterol levels are
decreased before surgery in patients with critical limb isch-
emia and rise 3 months after surgery. In contrast, C-reac-
tive protein decreased after bypass surgery. Furthermore,
an inverse linear relationship was established between the
rise of cholesterol values and the fall of C-reactive protein.
Thus, serum lipids seem to act as “inverse” acute phase
reactants. To our knowledge, however, nowhere in litera-
ture is there any biochemical explanation of this phenom-
enon.
These changes in cholesterol levels are well described
for acute coronary events.12-18 This paper supports these
results but suggests that the degree of cholesterol reduction
seen in patients with critical limb ischemia is more signifi-
cant and possibly longer lasting or chronic. A single study
has investigated the association between lipoproteins and
acute phase reactants in patients with myocardial infarc-
tion,19 but to our knowledge, this phenomenon has never
been described in patients with critical limb ischemia.
A number of prospective epidemiologic studies have
shown that serum total and LDL cholesterol can predict
coronary artery disease.20 Similarly, large randomized trials
have shown that both primary and secondary prevention
with cholesterol reduction with hydroxymethylglutaryl-
coenzyme A reductase inhibitors (statins) can yield signifi-
cant reductions in risk of nonfatal myocardial infarctions,
need for coronary bypass surgery or angioplasty, and coro-
nary death.1-5 Because it is recognized that patients with
peripheral arterial disease have an excessively high rate of
concomitant coronary artery disease,6 this is a group that
would be expected to benefit from treatment with statins.
Table II. Median preoperative and 3-month postoperative blood values
Median
preoperative Range
Median
postoperative Range P value
Total cholesterol (mmol/L) 4.5 1.2-6.6 5.4 3.4-8.7 .0001
LDL cholesterol (mmol/L) 2.4 0.4-4.5 3.2 1.4-5.9 .0001
HDL cholesterol (mmol/L) 1.2 0.4-2.0 1.5 0.7-2.4 .001
Triglycerides (mmol/L) 1.5 0.6-5.1 1.5 0.6-6.7 .08
Albumin (micromol/L) 422 211-649 579 394-704 .0001
C-reactive protein (mg/L) 35 3.0-300.0 6.5 1.0-100.0 .0001
Ankle pressure index (%) 0.39 0.0-0.71 0.87 0.45-1.1 .0001
Fig 2. Preoperative and postoperative total cholesterol in
mmol/L.
Fig 3. Preoperative and postoperative LDL cholesterol in
mmol/L.
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The recent Heart Protection Study showed that pa-
tients with peripheral arterial disease and without clinical
coronary artery disease had a reduction in the continued
cardiovascular endpoint. However, the study has not been
published, so exact data on the enrolled patients, random-
ization protocol, etc, remain unknown.9
Compared with healthy controls and individuals with
IHD, patients with critical ischemia had significantly lower
cholesterol levels even 3 months after surgery. This phe-
nomenon may have several explanations. First, lipid levels
may not have reached their maximum and assessment 3
months after surgery may be too early. Second, patients
with critical limb ischemia may have been ill for a longer
period of time before undergoing bypass surgery. This
could affect lipid values because nutritional status of the
patients is often suboptimal. Generally, albumin level may
be a useful marker of preoperative nutritional status. How-
ever, in this study, albumin levels were hampered by the
substantially elevated C-reactive protein level, a known
“depressor” of albumin. Conversely, that albumin in-
creased significantly after surgery may either be a result of
an improved nutritional status or because of resolved in-
flammation, evidenced by the decreased C-reactive protein.
Anyway, as national recommendations are based on actual
lipid values, the main result of this study, that lipid levels
measured around the time of surgery in this patient group
will result in too low values, remains a critical issue in daily
clinical practice. We did not address the question of dietary
history because no information on this matter was available
in the Copenhagen City Heart Study.
Finally, although 29 of 30 patients had patent bypass
grafts after 3 months, several still had tissue loss and ulcers
in the healing phase. This may also contribute to the lower
lipid levels observed in patients compared with controls.
Although lipid levels remained lower after 3 months, there
is evidence today that even at lower levels all patients with
atherosclerotic disease seem to benefit from lipid-lowering
therapy.9
Because subjects with critical limb ischemia often have
ongoing inflammatory processes from infections in necrotic
and ischemic tissue, C-reactive proteins may be a useful
marker for predicting when serum lipids are about to reach
their “normal” level. In light of this trend, the lipid levels of
a patient who after 3 months has persistent tissue loss or
ulcers and thereby elevated C-reactive protein should not
be regarded as baseline. Rather a normalization of the
inflammatory processes should be sought before evalua-
tion.
Although changes in lipid and acute phase reactant
levels have been noted for patients with myocardial infarc-
tion and stroke, the relationship has not been described for
patients with peripheral vascular disease. Lipids and acute
phase reactants are produced in the liver and hence inher-
ently related. However, to our knowledge, no proof exists
concerning the exact mechanism behind this lipid depres-
sion in acute and chronic illness.
Study limitations. One potential limitation of this
study was the risk of a type 2 error from the sample size of
30 patients. However, the observed statistical differences
were consistent and highly significant. Thus, we believe
that these differences are a true phenomenon and not a
result of multiple comparisons. Furthermore, the results are
in line with known lipid depression in other chronic ill-
nesses like stroke and IHD.
The study population may not be representative for the
entire critical limb ischemia population because none of
these consecutive patients were taking lipid-lowering
drugs. However, in Denmark and in most of the European
Fig 5. Correlation between change in total cholesterol and C-re-
active protein before and after surgery.
Fig 4. Preoperative and postoperative HDL cholesterol in
mmol/L.
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countries, patients with claudication or critical limb isch-
emia are not routinely given lipid-lowering treatment. Cur-
rent guidelines indicate benefit only in patients with IHD.
Furthermore, a study of 147 consecutive patients in our
clinic who underwent operation for critical limb ischemia in
1998 showed that only 5% received statins.7 Unfortunately,
we do not systematically register the use of lipid-lowering
treatment in our clinical database. Therefore, we are not
able to characterize this population further.
In conclusion, on the basis of these results, we suggest
that preoperative lipid profiles are deceptively low in pa-
tients with critical limb ischemia when inflammatory mark-
ers are strongly elevated. Reassessment is necessary at least
3 months after peripheral bypass surgery to approach a
more representative level.
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Table III. Comparison of lipid values for cases versus healthy and IHD controls from Copenhagen City Heart Study
Median value
(mmol/L)
Cases*
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(n  283) P value
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*Values for cases are postoperative.
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